wrap improv sale outlook
substanti invest
in-lin revenu ep miss con higher sg
ep rel line forecast miss consensu ep estim
higher-than-expect sg revenu guidanc midpoint came
our/consensu estim call y/i growth convers
ep guid came light ours/consensu midpoint reflect
substanti sale market invest expect drive top-line growth
notabl guidanc differ vs estim better growth outlook
three busi segment forecast notabl high single-digit y/i growth
expect north america vs flat midpoint guidanc sg margin
estim base result guidanc rais
revenu forecast sg result net
impact moder ep forecast period reiter
buy po ebitda vs ebitda prior
abat concern around us gener undemand valuat
area focu call
notabl updat gener advair management indic capac suppli
market comment access part plan impedi
uptak note gener access top part plan recal
myl g-copaxon initi block access part program acceler
sg spend management field numer question sg guidanc call
y/i increas spend versu spend declin management attribut
step-up sg increas invest need drive brand over-the-counter growth
intern well drive uptak specialty/complex product us market
strateg review updat call management note committe
near complet review morgantown management updat manufactur
remedi effort larg behind us anticip financi impact move
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
over-the-counter counter
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global pharmaceut compani
develop manufactur market
pharmaceut product span three segment
gener over-the-count brand specialti
product north american biggest market
account approxim total
sale follow europ
remaind rest world becom
one largest specialti gener player
combin organ growth
number signific acquisit
rate buy abat concern around
us gener industry-level gener price
show sign stabil improv new
integr undemand valuat
share trade impli ev/ebitda
multipl versu peer group averag
except ep
number share
price object po base multipl ebitda
rel gener peer believ share trade similar
multipl gener peer lower closest peer teva consensu
latter benefit low trough year uptick clinic
de-risk spec brand furthermor less visibl
earn profil view compani gener growth driver less durabl sourc
growth teva key spec brand believ dcf appropri
valuat methodolog littl visibl outlook beyond
one two year multipl take follow consider launch
g-advair gener advair relat conting payment mid-single-digit
growth eu row busi
risk po greater-than-expect competit pressur copaxon gener
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
